Moomoo AI 已提取核心信息
Alterity Therapeutics Limited, a development stage enterprise, has entered into a Sales Agreement with JonesTrading Institutional Services LLC on February 15, 2024. Under this agreement, Alterity Therapeutics may issue and sell American Depositary Shares (ADSs) through JonesTrading, which will act as the sales agent. The sales are to be conducted on an 'at the market offering' basis, as defined by Rule 415 of the Securities Act Regulations. JonesTrading will receive a 3% commission on the gross sales price of the shares sold. The ADSs will be offered up to a total of US$6,000,000, and this offering is pursuant to a Prospectus Supplement filed with the Securities and Exchange Commission on the same date. The shares will be issued under the company's effective Registration Statement on Form F-3. The company's counsel has provided an opinion on the validity of the shares to be issued, which is included as an exhibit in the report.
Alterity Therapeutics Limited, a development stage enterprise, has entered into a Sales Agreement with JonesTrading Institutional Services LLC on February 15, 2024. Under this agreement, Alterity Therapeutics may issue and sell American Depositary Shares (ADSs) through JonesTrading, which will act as the sales agent. The sales are to be conducted on an 'at the market offering' basis, as defined by Rule 415 of the Securities Act Regulations. JonesTrading will receive a 3% commission on the gross sales price of the shares sold. The ADSs will be offered up to a total of US$6,000,000, and this offering is pursuant to a Prospectus Supplement filed with the Securities and Exchange Commission on the same date. The shares will be issued under the company's effective Registration Statement on Form F-3. The company's counsel has provided an opinion on the validity of the shares to be issued, which is included as an exhibit in the report.
处于开发阶段的企业Alterity Therapeutics Limited已于2024年2月15日与琼斯贸易机构服务有限责任公司签订了销售协议。根据该协议，Alterity Therapeutics可以通过作为销售代理的JonesTrading发行和出售美国存托股票（ADS）。根据《证券法条例》第415条的规定，销售将在 “市场发行” 的基础上进行。JonesTrading将获得所售股票总销售价格的3％的佣金。ADS的发行总额将高达6,000,000美元，此次发行是根据同日向美国证券交易委员会提交的招股说明书补充文件进行的。股票将根据公司在F-3表格上的有效注册声明发行。该公司的法律顾问就即将发行的股票的有效性提供了意见，该意见作为证物包含在报告中。
处于开发阶段的企业Alterity Therapeutics Limited已于2024年2月15日与琼斯贸易机构服务有限责任公司签订了销售协议。根据该协议，Alterity Therapeutics可以通过作为销售代理的JonesTrading发行和出售美国存托股票（ADS）。根据《证券法条例》第415条的规定，销售将在 “市场发行” 的基础上进行。JonesTrading将获得所售股票总销售价格的3％的佣金。ADS的发行总额将高达6,000,000美元，此次发行是根据同日向美国证券交易委员会提交的招股说明书补充文件进行的。股票将根据公司在F-3表格上的有效注册声明发行。该公司的法律顾问就即将发行的股票的有效性提供了意见，该意见作为证物包含在报告中。
有用
没用